Kidney Cancer | Topics

Recap: Safety and Efficacy of Available Treatment Options and Considerations for Management of RCC
June 26, 2022

Experts share their thoughts on recent advances in treatment options for metastatic renal cell carcinoma and comment on emerging data in the field.

Adjuvant Everolimus Yields RFS Benefit Over Placebo in Very High-Risk Renal Cell Carcinoma
June 09, 2022

Patients with very high-risk renal cell carcinoma experienced a notable relapse-free survival benefit vs placebo following treatment with everolimus.

Data Support Lenvatinib Plus Pembrolizumab Combo as Standard of Care Treatment for Front-line Advanced RCC
June 05, 2022

Lenvatinib plus pembrolizumab decreased the risk of disease progression or death on second-line therapy by 50% compared with sunitinib in the phase 3 CLEAR trial.

Reduction in Risk of Recurrence or Death Observed With Adjuvant Everolimus for Very High-Risk RCC
June 04, 2022

Results of the phase 3 EVEREST trial show adjuvant everolimus improved recurrence-free survival for patients with very high-risk renal cell carcinoma.

OncView™ Podcast: Safety and Efficacy of Available Treatment Options and Considerations for Patient Management in Metastatic RCC
June 02, 2022

In an OncView™ program, David H. Aggen, MD, PhD, Robert S. Alter, MD, Arnab Basu, MD, MPH, FACP, Mehmet Asim Bilen, MD, and Chung-Han Lee, MD, MPH, offer their expert insights for the treatment of RCC.

Certain Subgroup in RCC Derives Promising Benefit from Neoadjuvant Axitinib
May 27, 2022

Interim results from the phase 2 PADRES trial demonstrated that partial nephrectomy may be possible for a subgroup of patients with clear cell renal cell carcinoma with complex masses who received neoadjuvant axitinib.

Selecting Patients for Treatment With Nivolumab ± Ipilimumab by Molecular Phenotype Yielded Positive Outcomes in Clear Cell RCC
May 27, 2022

Results from the phase 2 BIONIKK trial highlighted the feasibility and positive impact of selecting patients with metastatic clear cell renal cell carcinoma for treatment with nivolumab plus or minus ipilimumab and a VEGFR-tyrosine kinase inhibitor based on molecular phenotype.

The Importance of Team-Based Management and Patient Communication
May 25, 2022

Robert Alter, MD, comments on the importance of team-based care and frequent, timely communication in managing patients with RCC.

Clinical Pearls on Tailoring Dosing Strategies in Metastatic Kidney Cancer
May 25, 2022

David Aggen, MD, PhD, identifies dosing strategies that may maximize treatment efficacy while minimizing toxicity in patients with kidney cancer.

First-Line Lenvatinib Plus Pembrolizumab Yields Comparable in HRQOL Vs Sunitinib for Advanced RCC
May 20, 2022

Patients with advanced renal cell carcinoma who were treated with lenvatinib plus pembrolizumab had health-related quality of life comparable with sunitinib.